<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172976</url>
  </required_header>
  <id_info>
    <org_study_id>NEPAFOX</org_study_id>
    <nct_id>NCT02172976</nct_id>
  </id_info>
  <brief_title>Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma</brief_title>
  <official_title>Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicenter study, patients with resectable pancreatic carcinoma will be treated with
      (a) surgery followed by 6 cycles gemcitabine or (b) 6 cycles FOLFIRINOX followed by surgery
      followed by 6 cycles FOLFIRINOX.

      The overall survival between both therapies will be compared as well as other parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II/III randomized multicenter study. Patients with resectable pancreatic
      carcinoma will be randomized in Arm A (surgery plus adjuvant gemcitabine, 6 cycles) or Arm B
      (6 cycles FOLFIRINOX neoadjuvant, 6 cycles FOLFIRINOX adjuvant).

      Primary endpoint is the overall survival, secondary endpoints are progression-free survival,
      perioperative morbidity and mortality, rate of R0 resections, tolerability and feasibility of
      neoadjuvant FOLFIRINOX and others.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>median progression-free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression / relapse or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perioperative morbidity and mortality</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>2 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete remission</measure>
    <time_frame>at surgery</time_frame>
    <description>during surgery, paraffin embedded tissue is prepared for analysis which is analyzed for remission grading at the central pathology afterwards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (grade, number per patient) related to of G-CSF prophylaxis in the Folfirinox arm</measure>
    <time_frame>up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prevalence of iron deficiency</measure>
    <time_frame>baseline, d1 of every cycle, end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Resectable Prancreas Carcinoma</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natriumfolinate</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed ductal adenocarcinoma of the pankreas. For histological
             confirmation, max. 3 tests are allowed. If no confirmation of carcinoma is possible,
             the patient can not be included into the study.

          2. Radiological confirmation of a locally limited curativ resectable (primarily resectale
             or borderline situation) pankreas carcinoma without distant metastases.

          3. no prior pancreas resection

          4. no prior cytostatic chemotherapy

          5. Bilirubin &lt; 1,6 mg/dl

          6. female and male patients &gt; 18 years using contraception

          7. ECOG ≤ 1

          8. medical resectability

          9. granulocytes &gt; 1.500/µl

         10. thrombocytes &gt; 100.000/µl

         11. hemoglobin ≥ 8,0 g/dl

         12. serumcreatinine ≤ 1.5x of normal value or Creatinine-Clearance &gt; 50 ml/min

         13. written informed consent

        Exclusion Criteria:

          1. Endocrine and acinar pancreas carcinoma

          2. locally advanced inoperable stages: non-resectable infiltration of V. porta or longway
             infiltration of A. mesenterica superior or infiltration of Truncus coeliacus.

          3. distant metastases

          4. Relapse

          5. prior radiotherapy of measurable lesions

          6. peritonealcarcinosis

          7. malignant secondary disease, dated back &lt; 5 years (exeption: in-situ-carcinoma of the
             cervix, adequately treated skin basal cell carcinoma)

          8. contraindication for operative resection

          9. ECOG ≥ 2

         10. severe liver dysfunction (AST/ALT&gt;3,5xULN, AP&gt;6xULN, Bilirubin&gt;1,5xULN)

         11. Transhepatic drainage

         12. active CHD (symptoms present), cardiomyopathy or heart insufficiency stage III-IV
             according to NYHA and EF &lt; 45%

         13. severe non-surgical accompanying diseases or acute infection

         14. chronic diarrhea

         15. chronic inflammable gastro-intestinal disease

         16. peripheral polyneuropathy &gt; NCI grade II

         17. pregnancy or lactation

         18. hypersensibility or contraindication for Gemcitabine, Oxaliplatin, Natriumfolinate,
             Irinotecan or 5-Fluorouracil

         19. participation in another interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Reichart, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salah-Eddin Al-Batran, Prof.</last_name>
    <phone>+496976014420</phone>
    <email>albatran@khnw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Pauligk, PhD</last_name>
    <phone>+496976013906</phone>
    <email>pauligk.claudia@khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Reichart, MD</last_name>
      <phone>+496976014350</phone>
    </contact>
    <contact_backup>
      <last_name>Claudia Pauligk</last_name>
      <phone>+496976013906</phone>
      <email>pauligk.claudia@khnw.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ikf-nordwest.de/</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>Folfirinox</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

